52 North Health
52 North Health is a Cambridge-based medtech company building the proprietary Aster™ diagnostic platform with three pre-commercial products: Neutrocheck® for cancer patient neutropenic sepsis monitoring, ACORN™ for acute oncology triage, and ARC™ for nuclear emergency preparedness.
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What 52 North Health does
52 North Health is a Cambridge, UK-based medical technology company founded in 2018 as a spin-out from the University of Cambridge. It is developing a portfolio of in-vitro diagnostic and digital products built on its proprietary Aster™ platform — a patented lateral flow system capable of simultaneously measuring cell-based and soluble biomarkers from a single sample via an automated microfluidic process. The lead product, Neutrocheck®, is a portable finger-prick blood test paired with a companion app designed to detect neutropenic sepsis risk in chemotherapy patients by simultaneously measuring neutrophil count and C-reactive protein. ACORN™ is a web-based digital triage platform enabling real-time communication and clinical decision support between acute oncology nurses and patients, while ARC™, launched in 2025, extends the Aster™ platform to nuclear emergency preparedness and radiation sickness triage for defence and NATO applications. All three products are explicitly described as in development, not regulator-authorised, and not commercially available.
The company is pre-revenue with a B2B enterprise sales motion targeting healthcare systems, NHS trusts, pharmaceutical companies, and defence buyers. Expected revenue streams once commercialised include hardware and consumable sales for Neutrocheck®, subscription or licensing for ACORN™, co-development/licensing royalties from pharmaceutical and diagnostic partners, and defence contracts for ARC™. The company is piloting Neutrocheck® at multiple UK hospital sites including Addenbrooke's (with a 250-patient clinical trial planned) and has a 21-month collaboration with Cambridge University Hospitals NHS Foundation Trust, UK Sepsis Trust, Macmillan Cancer Support and UnifAI Technology. ACORN™ was co-developed with the East of England Cancer Alliance. A strategic collaboration with a global pharmaceutical company and co-development with one of the world's leading diagnostic companies for a remote platelet-measurement product indicate platform-licensing potential.
52 North Health has raised approximately $11M to date, anchored by a landmark $6M round in December 2024 co-led by KHP Ventures (UK) and Cedars-Sinai Intellectual Property Co. (US), the first transatlantic hospital-venture-fund co-led deal. Backers include Macmillan Cancer Support (its first-ever venture investment), Cancer Research Horizons, Meridian Health Ventures, OKG Capital, Cambridge Enterprise, NIHR grants, Innovate UK, and €400,000 from NATO DIANA. Neutrocheck® holds UK IDAP breakthrough status, and the company operates a ~20-person multidisciplinary team led by CEO Umaima Ahmad (former AstraZeneca billion-dollar oncology transactions) under Chair John Jeans CBE.
52 North Health firmographics
Firmographics- Name
- 52 North Health
- Legal name
- 52 North Health Ltd
- Website
- https://52north.health
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- 52 North Health is a Cambridge-based medtech company building the proprietary Aster™ diagnostic platform with three pre-commercial products: Neutrocheck® for cancer patient neutropenic sepsis monitoring, ACORN™ for acute oncology triage, and ARC™ for nuclear emergency preparedness.
- Ownership category
- akta.pro rank
52 North Health industry classification
Industry- Product category
- In-Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where 52 North Health is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
52 North Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Medical Device Sales (Neutrocheck): Neutrocheck is a portable finger-prick blood test device that detects biomarkers from a biological specimen. Revenue will be generated through sales of the device and associated consumables to healthcare providers and patients. Products mentioned on the site are in development and not currently available for sale.
- Digital Health Solutions (ACORN): ACORN is a web-based digital platform for acute oncology triaging. Revenue model likely subscription or licensing to healthcare providers and NHS trusts.
- Pharmaceutical Partnerships: Aster platform can be used by pharmaceutical companies to support drug development, drug safety and drug targeting. For example, Neutrocheck can be used to enable at-home treatment monitoring in clinical trials. Revenue could come from licensing, co-development agreements, or service fees.
- Co-development and Licensing: Strategic co-development opportunities with diagnostic companies. Working with one of the world's leading diagnostic companies to co-develop a new product that can remotely measure platelets using the Aster platform.
- Defence Sector (ARC): New product ARC for nuclear emergency preparedness backed by NATO. €400,000 received from NATO DIANA programme. Revenue opportunity through defence contracts and commercial adoption by NATO countries.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
52 North Health product offering
Product offeringCore offering
52 North Health develops in-vitro diagnostic medical devices and digital health solutions built on its proprietary Aster™ platform, which uses lateral flow technology to enable simultaneous measurement of cell-based and soluble biomarkers from a single sample. Its lead product Neutrocheck® is a portable finger-prick blood test and companion app that assesses neutrophil count and CRP to identify cancer patients at risk of neutropenic sepsis, while ACORN™ is a web-based digital triage platform for acute oncology. A third product, ARC™, applies the Aster platform to nuclear emergency preparedness for the NATO Alliance. All products are currently in development and have not yet received regulatory authorisation or been commercially launched.
Product overview
52 North Health is a med-tech company offering a portfolio of in-vitro diagnostic and digital solutions built on its proprietary Aster™ platform technology. The core product portfolio includes Neutrocheck®, a portable finger-prick blood test for cancer patients at risk of neutropenic sepsis, and ACORN™, a digital triage platform for acute oncology. A newer product, ARC™, extends the Aster™ platform for radiation sickness monitoring in defence applications. All products are designed to transform emergency care pathways by enabling remote patient monitoring and reducing unnecessary hospital admissions. Products mentioned on the site are in development and have not been authorised by regulators.
Differentiator
Problem solved
Functional benefit
Brands
- Neutrocheck®: A portable finger-prick blood test and app designed to help identify immunosuppressed patients who are at risk of neutropenic sepsis. The device detects biomarkers from a biological specimen and is accompanied by an app to assist patient decision-making.
- ACORN™
- Aster™
- ARC™
Products and services
- Neutrocheck® A portable finger-prick blood test and companion app that simultaneously measures neutrophil count and C-reactive protein (CRP) to identify immunosuppressed cancer patients at risk of neutropenic sepsis, enabling remote triage by clinicians and earlier antibiotic treatment. Targeted at NHS trusts, oncology services and patients undergoing chemotherapy.
- ACORN™ A web-based digital triage platform for acute oncology that provides real-time communication, built-in phone and messaging features, clinical decision support and AI-driven prioritisation tools for cancer nurses and patients managing emergency care needs.
- ARC™ A diagnostic product for nuclear emergency preparedness that enables remote triaging and treatment monitoring of individuals at risk of radiation sickness, ensuring rapid access to life-saving drugs. Developed for NATO alliance military and defence health stakeholders.
- Aster™ Platform (co-development and licensing) The world's first portable platform for cell measurement, offered for strategic co-development and licensing to pharmaceutical companies and diagnostics firms to support drug development, drug safety monitoring, drug targeting, and clinical trial endpoint measurement (e.g., co-development with a leading global diagnostics company on a platelet measurement product).
Quantifiable outcome
- 1 in 2 patients have normal neutrophils and may not have needed to attend the ER - significant reduction in unnecessary hospital visits
- +2 more outcomes
Companies that use 52 North Health
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
52 North Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
52 North Health partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, major and minor.
- Cambridge University Hospitals NHS Foundation Trustcore21-month collaboration partner for Neutrocheck clinical trials. Partnered with 52North, Macmillan, UK Sepsis Trust, UnifAI Technology for £1.2M Innovate UK Smart Grant project.
- UK Sepsis Trustmajor21-month collaboration partner for Neutrocheck expansion and clinical trials. Partnership aims to provide early identification of patients at risk of neutropenic sepsis and help save lives.
- UnifAI Technologymajor21-month collaboration partner for Neutrocheck solution expansion. Part of £1.2M Innovate UK Smart Grant collaboration.
- East of England Cancer AlliancecoreCollaborative partner in development of ACORN digital triage platform. Built ACORN in collaboration with East of England Cancer Alliance and with NIHR support.
- University of Cambridgecore52North spun out from University of Cambridge in 2018 by postgraduates. Ongoing research partnerships including KTP collaboration with Sormanni lab in Department of Chemistry. Cambridge Enterprise led £1M investment and continues to support 52North's journey.
- Imperial College LondonmajorStrategic partnership with renowned UK research institution demonstrating commitment to fostering innovation in MedTech.
- Histoindex Pte LtdminorCompany chaired by John Jeans CBE, newly appointed Chair of 52North. John brings extensive leadership experience from this and other medtech companies.
- Digital Health and Care Innovation CenterminorOrganization chaired by John Jeans CBE, newly appointed Chair of 52North. Connection through board leadership expertise.
- Singapore Government's Diagnostics HubminorJohn Jeans CBE co-chairs Singapore Government's Diagnostics Hub, bringing international strategic perspective to 52North.
- Texas Medical Center Innovation (TMCi)major52North selected for prestigious digital health accelerator to refine US go-to-market plan. Gains access to TMCi's remarkable facilities, cutting-edge infrastructure, extensive network, and curated programming.
- Cedars-Sinai AcceleratormajorSelected for 9th class of Cedars-Sinai Accelerator. Three-month programme offering mentorship, $100,000 investment, and hands-on experience from Cedars-Sinai experts.
- Global Pharmaceutical CompanycoreStrategic collaboration signed with a global pharmaceutical company, mentioned in December 2024 announcement. Partnership will enable product pipeline expansion using Aster platform technology.
- Leading Diagnostic CompanycoreWorking with one of the world's leading diagnostic companies to co-develop a new product that can remotely measure platelets using the Aster platform.
- Nordic Mentor Network for Entrepreneurship (NOME)majorWon NOME Startup Competition 2024 securing DKK 50,000 prize and admission into renowned NOME Mentoring Program. Programme connects startups with top-tier professionals for regulatory compliance, pricing strategies, market access, and business modelling expertise.
- Renishaw plcminorJohn Jeans CBE serves on board of Renishaw plc (LSE: RSW; £2bn market cap). Connection through board leadership expertise.
Scale indicators9 records
Recent moves7 records
Expansion highlights7 records
52 North Health competitors and assessment
Company assessmentDirect peers
- Abingdon Health: UK-based lateral flow diagnostics contract developer and product company. Directly comparable to 52North in core lateral flow technology, point-of-care diagnostic focus, and target customer base (healthcare providers and consumer health).
- Mologic: UK-based rapid diagnostics developer specializing in lateral flow and point-of-care tests, including at-home and clinical settings. Comparable lateral flow technology stack and focus on accessible, low-cost diagnostics for global health.
- Angle plc: UK-based liquid biopsy and cancer diagnostics company. Comparable as a UK oncology diagnostics developer pursuing FDA and CE marked approvals, serving similar oncology clinical research and clinical use cases.
- VolitionRx: Multinational cancer diagnostics developer focused on blood-based biomarker tests for oncology. Comparable in mission (blood-based cancer diagnostics) and commercial-stage medtech execution against large incumbents.
- QuantuMDx: UK-based developer of rapid point-of-care molecular diagnostic devices. Comparable in mission (portable, rapid diagnostics) and customer base (NHS trusts, global health), with similar device-plus-consumable revenue model.
- Oncimmune Holdings: UK-based immunodiagnostics company developing blood-based tests for early cancer detection. Comparable in oncology-focused blood diagnostics commercial model and NHS-aligned customer base.
Regional players
- Owlstone Medical: Cambridge, UK-based diagnostics company developing breath-based biomarker tests for cancer and other diseases. Comparable as a Cambridge spin-out diagnostics company pursuing non-invasive, decentralised diagnostic testing.
Broad incumbents
- Roche Diagnostics: Global leader in in-vitro diagnostics and point-of-care testing. Represents the established incumbent whose lateral flow and immunoassay infrastructure 52North is ultimately competing with for hospital and clinical diagnostics budgets.
- Abbott Point of Care: Major diagnostics incumbent with i-STAT and other bedside/point-of-care platforms used in hospitals globally. Comparable as the type of established platform 52North's Neutrocheck would compete with once commercialized.
Emerging players
- Cizzle Biotech: UK early-stage cancer diagnostics developer focused on blood-based biomarker detection. Comparable as a small UK oncology diagnostics player working toward commercialization through NHS and global channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
52 North Health social profiles
Digital presence52 North Health compliance and trust
Trust signalCompliance1 record
52 North Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
52 North Health leadership team
Management profileNumber of profiles
Profiles7 records
52 North Health funding detail
Funding detailFunding overview
Funding rounds10 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
52 North Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 52 North Health
What does 52 North Health do?
52 North Health develops in-vitro diagnostic medical devices and digital health solutions built on its proprietary Aster™ platform, which uses lateral flow technology to enable simultaneous measurement of cell-based and soluble biomarkers from a single sample. Its lead product Neutrocheck® is a portable finger-prick blood test and companion app that assesses neutrophil count and CRP to identify cancer patients at risk of neutropenic sepsis, while ACORN™ is a web-based digital triage platform for acute oncology. A third product, ARC™, applies the Aster platform to nuclear emergency preparedness for the NATO Alliance. All products are currently in development and have not yet received regulatory authorisation or been commercially launched.
Is 52 North Health a public or private company?
52 North Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was 52 North Health founded?
52 North Health was founded in 2018. It employs 11 to 50 people.
Where is 52 North Health based?
52 North Health is headquartered in Cambridge, United Kingdom, in the Europe region.
How does 52 North Health make money?
Five revenue lines are on record. Medical Device Sales (Neutrocheck) is the primary driver. The others are digital Health Solutions (ACORN), pharmaceutical Partnerships, co-development and Licensing and defence Sector (ARC).
Who are 52 North Health's main competitors?
Direct peers on record are Abingdon Health, Mologic, Angle plc, VolitionRx, QuantuMDx and Oncimmune Holdings. Owlstone Medical is listed as a regional player. Broad incumbents are Roche Diagnostics and Abbott Point of Care. Cizzle Biotech is listed as an emerging player.
Does 52 North Health have an API?
No public API is recorded for 52 North Health.
What industry is 52 North Health in?
52 North Health's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.